Bioavailability of dihydroergotamine.
作者信息
Kanto J
出版信息
Br Med J. 1980 Sep 13;281(6242):748. doi: 10.1136/bmj.281.6242.748.
Abstract
摘要
相似文献
1
Bioavailability of dihydroergotamine.双氢麦角胺的生物利用度。
Br Med J. 1980 Sep 13;281(6242):748. doi: 10.1136/bmj.281.6242.748.
2
Nasal absorption of dihydroergotamine from liquid and powder formulations in rabbits.兔体内液体和粉末制剂中双氢麦角胺的鼻腔吸收情况。
J Pharm Sci. 1997 Jul;86(7):802-7. doi: 10.1021/js960500j.
3
Low bioavailability as a cause of apparent failure of dihydroergotamine in orthostatic hypotension.生物利用度低作为双氢麦角胺治疗直立性低血压明显无效的原因。
Br Med J. 1980 Jul 26;281(6235):275-6. doi: 10.1136/bmj.281.6235.275-a.
4
[Comparative bioavailability of two oral forms of dihydroergotamine (author's transl)].两种口服形式双氢麦角胺的比较生物利用度（作者译）
Therapie. 1979 Sep-Oct;34(5):625-34.
5
The pharmacokinetics of dihydroergotamine in the beagle.
Int J Clin Pharmacol Biopharm. 1978 Mar;16(3):124-8.
6
Absorption and excretion of dihydroergocristine and dihydroergotamine in the dog.双氢麦角汀和双氢麦角胺在犬体内的吸收与排泄
Farmaco Prat. 1978 Nov;33(11):477-83.
7
8
Significance of the goblet-cell mucin layer, the outermost luminal barrier to passage through the gut wall.杯状细胞粘蛋白层作为穿过肠壁的最外层管腔屏障的意义。
Biochem Biophys Res Commun. 1980 Jun 16;94(3):960-6. doi: 10.1016/0006-291x(80)91328-5.
9
10
[Plasma levels and biliary and urinary elimination of raubasine, dehydroergocristine and dihydroergotamine after venous administration in anesthetized dogs].[麻醉犬静脉注射后萝巴新、脱氢麦角隐亭和双氢麦角胺的血浆水平及胆汁和尿液排泄情况]
Boll Soc Ital Biol Sper. 1975 Jun 15;51(11):684-6.
本文引用的文献
1
Intramuscular absorption of dihydroergotamine in man.双氢麦角胺在人体中的肌肉注射吸收情况。
Int J Clin Pharmacol Biopharm. 1978 Jun;16(6):277-8.
2
The pharmacokinetics of dihydroergotamine in the beagle.
Int J Clin Pharmacol Biopharm. 1978 Mar;16(3):124-8.
3
Dihydroergotamine: pharmacokinetics and usefulness in spinal anaesthesia.
Acta Anaesthesiol Scand. 1978;22(3):215-20. doi: 10.1111/aas.1978.22.3.215.
Zotero 插件